Royalty Pharma Plc. (RPRX) on Tuesday announced a $2 billion funding arrangement with Revolution Medicines (RVMD), aimed at ...

Royalty Pharma is less exposed to MFN drug pricing risks, offering downside protection in a volatile policy environment. See ...

Royalty Pharma will pay up to $2 billion to Revolution Medicines to support the development and sales of an experimental drug ...

Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology firm focused on targeted treatments for RAS-driven ...

Revolution Medicines projected its cash and equivalents of $2.1 billion would last into the second half of 2027. With new ...

A total of $1.25 billion of the money pledged by Royalty has been agreed in exchange for tiered royalties on net sales of ...

Revolution Medicines and Summit Therapeutics entered into a clinical collaboration in multiple solid-tumor settings to evaluate their respective treatments in combination with each other. Redwood City ...

Up to $1.25 billion ($250 million upfront) of synthetic royalty funding and up to $750 million in secured debt ; Innovative partnership enables Revolution Medicines to retain control over pipeline ...

Revolution Medicines, Inc. Transaction on Track to Close in November 2023. REDWOOD CITY, Calif. and CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a ...

Revolution Medicines raised $238 million via its 2020 IPO, and 4 years later has grown its share price by ~30%, bringing its market cap valuation to $6 billion.

REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS ...

--Royalty Pharma plc today announced a $2 billion funding arrangement with Revolution Medicines, consisting of a synthetic royalty of up to $1.25 billion on daraxonrasib and a senior secured loan ...